The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Borrower

A•••••• M•••••••• T••••••••

Drug Discovery & Developmentgroup grade Aoff every schedule since Sep 30, 2023sponsor unattributed
Also written as: Equity
See every lender's markFind rescue capital
More
Special situations PE firms

Nothing material in the last 200 days. No dated change on record yet.

Principal held
unknown
sum of BDC pieces, a lower bound
Fair value
$0
n/a on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
0
1 equity pieces beside them
Next maturity
unstated
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Sep 30, 2023
Events
0
dated, non-routine
Lender marks
each lender's own fair value over cost at Sep 30, 2023, folded to one row per lender
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
BDCInstrumentPrincipalFair valueRate
H••••••• C••••••• I•••equity equity
A••••••••• D••• 4/6/2021, Series C••••• S••••
Not disclosed$0
0c
Capital structure as the BDCs see it
latest quarter end Sep 30, 2023
No debt facility on the tape for this borrower; the BDC pieces are equity.
Equity pieces beside the debt: equity ($0 fair value, 1 BDC)
Through time
the borrower's pieces summed across BDCs, every quarter end
Quarter endBDCsPrincipal heldFair valueOn costPIK pieces
Sep 30, 20231$0$0n/a0
Jun 30, 20231$0$0n/a0
Mar 31, 20231$0$0n/a0
Dec 31, 20221$0$0n/a0
What changed
No non-routine event yet: the borrower has been held without a facility-level change since it appeared.
Every change including routine ones
Identity
Group key
A•••••• M•••••••• T••••••••derivedthe codename stem after legal suffixes and deal words
Spellings
1 across 1 BDCderived
Industry
Drug Discovery & Developmentreportedas one filer wrote it